
|Articles|April 15, 2022
Daily Medication Pearl: Ponesimod (Ponvory)
Author(s)Saro Arakelians, PharmD
Ponesimod (Ponvory) is indicated for the treatment of relapsing forms of multiple sclerosis.
Advertisement
Medication Pearl of the Day: Ponesimod (Ponvory)
Indication: Ponesimod (Ponvory) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Insight:
- Dosing: The recommended maintenance dosage is 20 mg taken orally once daily.
- Dosage forms: Tablets 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, and 20 mg.
- Adverse events: Most common adverse reactions (incidence at least 10%) are upper respiratory tract infection, hepatic transaminase elevation, and hypertension.
- Mechanism of action: Ponesimod is a sphingosine 1-phosphate (S1P) receptor 1 modulator that binds with high affinity to S1P receptor 1.
- Manufacturer: Janssen Pharma
Source
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
ADCs in Breast Cancer: Shaping the Future of HER2– and TROP2-Targeted Therapy
2
FDA Approves Gepotidacin for Urogenital Gonorrhea in Adult and Pediatric Patients
3
Emerging Data from the DESTINY-Breast Trials Signal Shift in Standards of Care for HER2-Positive Breast Cancer
4
Study: Many Patients Switching Biologics Because of Perceived Lack of Efficacy Treating Asthma
5





















































































































































































































